Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salvinorin A is a naturally occurring trans-neoclerodane diterpenoid and the principal psychoactive compound found in the plant Salvia divinorum. It is unique among hallucinogens as it is not an alkaloid and lacks a basic nitrogen atom. Salvinorin A acts as a highly potent and selective agonist of the kappa opioid receptor (KOR), with activity at doses as low as 200 micrograms. Unlike classical psychedelics, it does not act on serotonin 5-HT2A receptors but has been shown to have some effect on dopamine D2 receptor (partial agonist) and cannabinoid CB1 receptor. Its effects are characterized by intense but short-lived hallucinations, dissociation, sedation, dysphoria, and alterations in perception. Due to rapid metabolism—primarily hydrolysis to inactive salvinorin B—and poor oral bioavailability, its psychoactive effects are brief when administered via non-oral routes such as smoking or buccal absorption. Research has explored potential therapeutic applications for salvinorin A in neuropsychiatric disorders (such as depression), addiction treatment, acute brain injury (including ischemic stroke), and neuroprotection due to its ability to modulate abnormal neuronal activity patterns[1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Salvinorin A.